On July 19 2021 Luminary Therapeutics reported that it was selected as a 2022/2023 Showcase Company in NIH/NCI’s investor initiative program (Press release, Luminary Therapeutics, JUL 19, 2022, View Source;utm_medium=rss&utm_campaign=luminary-therapeutics-selected-as-a-2022-2023-showcase-company-in-nih-ncis-investor-initiative-program [SID1234617162]). Luminary Therapeutics is a clinical stage allogeneic cellular therapy company. Its gamma delta expansion platform coupled with its non-viral cell engineering process is unique in the industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Luminary Therapeutics’ novel ligand-based CAR designed to bind three targets is set to enter the clinic in the early Fall of 2022 to treat Mantle Cell Cancer and Multipe Myeloma with its LMY-920 Cell Therapy. This BAFF CAR-T product was developed by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.

"This recognition by the NIH is a validation on the thoughtful work completed to bring this cell therapy into the clinic. Luminary achieved this clinical milestone in a short two year period attributable to our ability to manufacture a cell therapy with a significantly lower cost and reduced time to clinic via a non-viral gene modification manufacturing method," said Jeff Liter Luminary’s CEO.

On July 19, 2022 Novartis reported second quarter and half year 2022 results (Presentation, Novartis, JUL 19, 2022, View Source [SID1234616880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 19, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions (Press release, Revolution Medicines, JUL 19, 2022, View Source [SID1234616786]). All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be $230.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 22, 2022, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, Cowen and Guggenheim Securities are acting as the joint book-running managers for the proposed offering.

A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission on March 2, 2021, and automatically became effective upon filing. This offering is being made solely by means of a prospectus. A copy of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at [email protected]; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On July 19, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology leader, reported that it was recently awarded a follow-on contract to support the Navy’s Program Executive Office Integrated Warfare Systems Directorate (Press release, Leidos, JUL 19, 2022, View Source [SID1234616785]). The single award, cost-plus-fixed-fee contract holds an approximate value of $291 million. It includes a one-year base period of performance with four additional one-year option periods. Work will be performed worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to continue our long-standing relationship with PEO IWS," said Will Johnson, Leidos Senior Vice President, Logistics and Mission Support. "This award will enable Leidos to accelerate our support of their critical mission through modernization, domain expertise and innovation."

Through this contract, Leidos will perform a range of support services, including shipboard modernization, curriculum development, training conduct, depot support, technical data, maintenance planning and management.

Headquartered in Washington D.C., the Program Executive Office Integrated Warfare Systems Directorate develops, delivers and sustains operationally dominant combat systems for the U.S. Navy.